Literature DB >> 11353728

Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex.

V Kaasinen1, E Nurmi, A Brück, O Eskola, J Bergman, O Solin, J O Rinne.   

Abstract

Previous imaging studies in Parkinson's disease have focused mainly on the striatum, a region with very high dopaminergic activity. Using modern high-sensitivity 3D [(18)F]fluorodopa (Fdopa)-PET, mesocortical monoamine projections can be studied. To study the frontal monoaminergic system in unmedicated early Parkinson's disease in vivo, we examined 20 early Parkinson's disease patients (10 women, 10 men) and 16 healthy subjects (nine women, seven men) with 3D Fdopa-PET, using standard region-of-interest-based analysis with MRI co-registration. Women with Parkinson's disease had 87% higher Fdopa uptake in the right dorsolateral prefrontal cortex (area 46) compared with men with Parkinson's disease, whereas there was no sex difference in the control group (sex x disease interaction, P = 0.03). The uptake in the right dorsolateral prefrontal cortex was 82% higher in men with Parkinson's disease and 219% higher in women with Parkinson's disease compared with control groups (effect of disease, P < 0.0001). Also in the left dorsolateral prefrontal cortex and in the medial frontal cortex, early Parkinson's disease patients had significantly (18-94%) higher Fdopa uptake compared with healthy controls. In the putamen, both men and women with Parkinson's disease had a significantly lower (27-46%) uptake compared with healthy controls. These results indicate that frontal monoaminergic activity is increased and that there is a sex difference in the prefrontal monoaminergic system in early Parkinson's disease. The reported sex difference may be linked to clinical sex differences in the symptoms and treatment response in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353728     DOI: 10.1093/brain/124.6.1125

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  48 in total

1.  Personality traits and brain dopaminergic function in Parkinson's disease.

Authors:  V Kaasinen; E Nurmi; J Bergman; O Eskola; O Solin; P Sonninen; J O Rinne
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome.

Authors:  Christina Zaleski; Anne S Bassett; Karen Tam; Andrea L Shugar; Eva W C Chow; Elizabeth McPherson
Journal:  Am J Med Genet A       Date:  2009-03       Impact factor: 2.802

3.  Enhanced frontal function in Parkinson's disease.

Authors:  R Cools; A Miyakawa; M Sheridan; M D'Esposito
Journal:  Brain       Date:  2009-12-07       Impact factor: 13.501

4.  The role of the right dorsolateral prefrontal cortex in the Tower of London task performance: repetitive transcranial magnetic stimulation study in patients with Parkinson's disease.

Authors:  H Srovnalova; R Marecek; R Kubikova; I Rektorova
Journal:  Exp Brain Res       Date:  2012-09-14       Impact factor: 1.972

Review 5.  Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise.

Authors:  Jennifer C Felger; Andrew H Miller
Journal:  Front Neuroendocrinol       Date:  2012-09-21       Impact factor: 8.606

Review 6.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

7.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

Review 8.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

Review 9.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 10.  Medial prefrontal cortex in neurological diseases.

Authors:  Pan Xu; Ai Chen; Yipeng Li; Xuezhi Xing; Hui Lu
Journal:  Physiol Genomics       Date:  2019-08-02       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.